Across TCGA pan-cancer cohorts, S100A7A Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated S100A7A data layer compared with 19 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher S100A7A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated S100A7A expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.
BLCA, BRCA, and LUAD are the cancer types where S100A7A Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.